OA07069A - Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation. - Google Patents

Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation.

Info

Publication number
OA07069A
OA07069A OA57657A OA57657A OA07069A OA 07069 A OA07069 A OA 07069A OA 57657 A OA57657 A OA 57657A OA 57657 A OA57657 A OA 57657A OA 07069 A OA07069 A OA 07069A
Authority
OA
OAPI
Prior art keywords
ricin
preparation
cancer drugs
drugs containing
chain associated
Prior art date
Application number
OA57657A
Other languages
English (en)
French (fr)
Inventor
Jansen Franz Klauss
Gros Pierre
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of OA07069A publication Critical patent/OA07069A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA57657A 1981-04-15 1982-04-13 Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation. OA07069A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8107596A FR2504010B1 (fr) 1981-04-15 1981-04-15 Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation

Publications (1)

Publication Number Publication Date
OA07069A true OA07069A (fr) 1984-01-31

Family

ID=9257448

Family Applications (1)

Application Number Title Priority Date Filing Date
OA57657A OA07069A (fr) 1981-04-15 1982-04-13 Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation.

Country Status (30)

Country Link
US (1) US4414148A (de)
EP (1) EP0063988B1 (de)
JP (1) JPS57179124A (de)
KR (1) KR880001045B1 (de)
AR (1) AR228394A1 (de)
AT (1) ATE17653T1 (de)
AU (1) AU556641B2 (de)
CA (1) CA1195248A (de)
CZ (1) CZ256482A3 (de)
DD (1) DD204849A5 (de)
DE (1) DE3268752D1 (de)
DK (1) DK159277C (de)
EG (1) EG15718A (de)
ES (1) ES511433A0 (de)
FI (1) FI76693C (de)
FR (1) FR2504010B1 (de)
GR (1) GR69199B (de)
HU (1) HU188314B (de)
IE (1) IE53009B1 (de)
IL (1) IL65441A0 (de)
MA (1) MA19429A1 (de)
NO (1) NO154905C (de)
NZ (1) NZ200302A (de)
OA (1) OA07069A (de)
PH (1) PH20846A (de)
PL (1) PL135800B1 (de)
PT (1) PT74741B (de)
SU (1) SU1329604A3 (de)
YU (1) YU83082A (de)
ZA (1) ZA822528B (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
DE3369466D1 (en) * 1982-05-12 1987-03-05 Harvard College Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
JPS5990052A (ja) * 1982-11-16 1984-05-24 Katsu Taniguchi モノクロ−ナル特異抗体を用いたメラノ−マ診断薬
US4916213A (en) * 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
US4591572A (en) * 1983-04-01 1986-05-27 Sloan-Kettering Institute For Cancer Research Pigmentation associated, differentiation antigen of human melanoma and autologous antibody
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
GB2142428A (en) * 1983-06-23 1985-01-16 Erba Farmitalia Adenocarcinoma related antigenic determinants and antibodies specific thereto
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
FR2570278B1 (fr) * 1984-09-14 1987-02-13 Pasteur Institut Compositions et procede pour proteger les lymphocytes t contre l'agent etiologique des lymphadenopathies et du syndrome d'immunodepression acquise
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
EP0232447A1 (de) * 1986-02-13 1987-08-19 Xoma Corporation Lektin-Immunotoxine
AU585940B2 (en) * 1984-09-25 1989-06-29 Xoma Corporation Lectin immunotoxins
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
US4851510A (en) * 1984-11-30 1989-07-25 Wadley Technologies, Inc. Monoclonal antibodies to novel melanoma-associated antigens
US5256413A (en) * 1985-01-08 1993-10-26 The General Hospital Corporation Method and use for site-specific activation of substances
AT384549B (de) * 1985-01-08 1987-11-25 Strasser Engelbert Verfahren zur herstellung einer vaccine
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
US4744981A (en) * 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
AU609380B2 (en) * 1985-11-29 1991-05-02 Consolidated Pharmaceuticals Limited Ricin-antibody conjugates
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
US4689401A (en) * 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5009995A (en) * 1986-10-27 1991-04-23 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to melanoma cells
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
IE910820A1 (en) * 1990-03-22 1991-09-25 Sloan Kettering Inst Cancer Gp75 as a tumor vaccine for melanoma
NZ237688A (en) * 1990-04-19 1993-01-27 Res Dev Foundation Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment
US5981194A (en) * 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
US5690935A (en) * 1995-01-13 1997-11-25 Regents Of The University Of Minnesota Biotherapy of cancer by targeting TP-3/P80
EP0873363B1 (de) 1995-06-14 2010-10-06 The Regents of The University of California Hochaffine humane antikörper gegen tumorantigene
WO1998012334A2 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
US6869604B1 (en) * 1998-03-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant anti-tumor RNAse
PT1075277E (pt) * 1998-05-08 2009-05-08 Univ California Métodos para detectar e inibir a angiogénese
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
DE60137953D1 (de) 2000-10-06 2009-04-23 Life Technologies Corp Zellen mit spektraler signatur sowie verfahren zu ihrer herstellung und nutzung
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
EP2381116A1 (de) 2000-11-16 2011-10-26 California Institute of Technology Vorrichtungen und Verfahren zur Durchführung von Tests und Screening mit hohem Durchsatz
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
WO2002100172A1 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Administration of agents via the pept-2 transporter
EP1414471B1 (de) 2001-07-17 2012-06-13 Research Development Foundation Therapeutische Mittel mit pro-apoptotischen Proteinen
CA2467587A1 (en) 2001-11-30 2003-06-12 Fluidigm Corporation Microfluidic device and methods of using same
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
US20030158089A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Administrative agents via the SMVT transporter
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US20030228619A1 (en) * 2002-06-10 2003-12-11 Xenoport, Inc. Peptide nucleic acids as tags in encoded libraries
EP1572170A4 (de) * 2002-06-12 2007-02-28 Res Dev Foundation Immunotoxin als therapeutisches mittel und seine verwendungen
RU2326691C2 (ru) 2002-07-18 2008-06-20 Хеликс Биофарма Корп. Использование уреазы для ингибирования роста раковых клеток
US20040161424A1 (en) * 2002-10-08 2004-08-19 Xenoport Human organic solute transporters
US7666361B2 (en) 2003-04-03 2010-02-23 Fluidigm Corporation Microfluidic devices and methods of using same
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
WO2006069220A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Modified human growth hormone
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
MX2007000728A (es) 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
WO2006053380A1 (en) * 2004-11-16 2006-05-26 Sienna Cancer Diagnostics Ltd Methods of detecting an analyte in a sample
CA2927595C (en) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
AU2005319518B2 (en) * 2004-12-22 2010-09-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
KR101224781B1 (ko) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
EP1855724A2 (de) * 2005-02-01 2007-11-21 Research Development Foundation Blys-fusionsproteine für targeting des blys-rezeptors und verfahren zur behandlung von proliferativen b-zell-störungen
EP2371453A1 (de) 2005-03-18 2011-10-05 Fluidigm Corporation Mikrofluide Vorrichtung
US20100135959A1 (en) * 2005-06-03 2010-06-03 Ambrx, Inc. Human Interferon Molecules and Their Uses
EP1937824B1 (de) * 2005-08-18 2013-03-13 Ambrx, Inc. trna-zusammensetzungen und deren verwendungen
CA2625540C (en) * 2005-11-08 2017-03-21 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
US20080317670A1 (en) * 2005-12-14 2008-12-25 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
EP2061878B1 (de) * 2006-09-08 2014-01-08 Ambrx, Inc. Hybridunterdrücker-trna für wirbeltierzellen
PT2064333E (pt) * 2006-09-08 2014-06-09 Ambrx Inc Supressor híbrido arnt para células de vertebrados
EP2842570B1 (de) * 2007-03-07 2020-05-06 UTI Limited Partnership Zusammensetzungen und verfahren zur prävention und behandlung von autoimmunkrankheiten
HRP20120522T1 (hr) 2007-03-30 2012-08-31 Ambrx Modificirani fgf-21 polipeptidi i njihova uporaba
CN103965347B (zh) * 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
EP2348052A3 (de) 2007-09-17 2011-10-26 The Regents of The University of California Auf Prostatazellen in situ abzielende internalisierende humane monoklonale Antikörper
MX2010003099A (es) 2007-09-21 2010-05-17 Univ California Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
IL198123A0 (en) 2008-04-18 2009-12-24 Snecma Propulsion Solide A heat treatment oven with inductive heating
WO2009148896A2 (en) 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
PT2318029T (pt) * 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
MX2011003196A (es) 2008-09-26 2011-04-27 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
DK2342223T3 (en) 2008-09-26 2017-07-24 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
CN102438580B (zh) 2009-02-06 2015-06-17 加利福尼亚大学董事会 钙结合剂诱导毛发生长和/或甲生长
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP2516455A4 (de) 2009-12-21 2013-05-22 Ambrx Inc Modifizierte schweine-somatotropin-polypeptide und deren verwendungen
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
PH12013500241A1 (en) 2010-08-17 2013-03-11 Ambrx Inc Modified relaxin polypeptides and their uses
BR112013006088B1 (pt) 2010-09-15 2022-06-14 Randall J Mrsny Construto de entrega isolado, e, composição farmacêutica
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN105497883A (zh) 2010-09-29 2016-04-20 乌第有限合伙公司 使用生物相容性的生物可吸收纳米球治疗自身免疫病的方法
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
AU2012229156A1 (en) 2011-03-11 2013-10-31 Board Of Regents Of The University Of Nebraska Biomarker for coronary artery disease
EP2694095B1 (de) 2011-04-05 2018-03-07 Longevity Biotech, Inc. Zusammensetzungen mit glukagon-analogen sowie verfahren zu ihrer herstellung und verwendung
CA2837167A1 (en) 2011-05-27 2012-12-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
DK2714684T3 (en) 2011-05-27 2018-11-26 Ambrx Inc COMPOSITIONS CONTAINING, PROCEDURE INVOLVING, AND APPLICATIONS OF NON-NATURAL AMINO ACID-BONDED DOLASTATIN DERIVATIVES
PT2822575T (pt) 2012-03-03 2020-07-02 Immungene Inc Moléculas de fusão anticorpos-mutante de interferão modificadas
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
WO2013185117A1 (en) 2012-06-07 2013-12-12 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
KR20150023729A (ko) 2012-06-14 2015-03-05 암브룩스, 인코포레이티드 핵 수용체 리간드 폴리펩티드에 접합된 항-psma 항체
EP3488870B1 (de) 2012-06-19 2024-03-20 Ambrx, Inc. Anti-cd70-antikörper-arzneimittelkonjugate
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
CA2908475C (en) 2013-04-08 2020-09-08 Helix Biopharma Corp. Use of antibody-urease conjugates for diagnostic and therapeutic purposes
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US10519247B2 (en) 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
FR3018526B1 (fr) 2014-03-14 2021-06-11 Herakles Installation de densification cvi comprenant une zone de prechauffage a forte capacite
BR112016025866A2 (pt) 2014-05-07 2017-12-12 Applied Molecular Transp Llc composição farmacêutica, método para tratar uma doença anti-inflamatória em um indivíduo, método para tratar uma doença autoimune em um indivíduo, método para tratar um câncer em um indivíduo, uso de uma molécula de fusão que não ocorre naturalmente, método para tratar um distúrbio metabólico em um indivíduo, método para tratar uma doença hepática gordurosa em um indivíduo, método para tratar um distúrbio de deficiência de hormônio de crescimentoem um indivíduo, e, polinucleotídeo que codifica uma molécula de fusão
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
JP6920211B2 (ja) 2015-05-06 2021-08-18 ユーティーアイ リミテッド パートナーシップ 持続療法用のナノ粒子組成物
NZ743049A (en) 2015-11-03 2025-08-29 Ambrx Inc Anti-cd3-folate conjugates and their uses
PT3383920T (pt) 2015-11-30 2024-04-15 Univ California Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
WO2017180789A2 (en) 2016-04-12 2017-10-19 Blaze Bioscience, Inc. Methods of treatment using chlorotoxin conjugates
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
WO2018089829A1 (en) 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
WO2018089807A2 (en) 2016-11-11 2018-05-17 The Regents Of The University Of California Anti-cd46 antibodies and methods of use
WO2018111782A1 (en) 2016-12-12 2018-06-21 Cepheid Integrated immuno-pcr and nucleic acid analysis in an automated reaction cartridge
CN110300595A (zh) 2017-01-05 2019-10-01 加利福尼亚大学董事会 Pac1受体激动剂(maxcap)及其用途
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
JP7436372B2 (ja) 2017-11-29 2024-02-21 ユーティアイ・リミテッド・パートナーシップ 自己免疫性疾患を治療する方法
KR20210076881A (ko) 2018-03-08 2021-06-24 어플라이드 몰레큘라 트랜스포트 인크. 경구 전달용 독소-유래 전달 구조체
AU2019230230B2 (en) 2018-03-08 2025-04-10 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
BR112020019611A2 (pt) 2018-03-29 2021-01-05 Ambrx, Inc. Conjugados de anticorpo anti-antígeno de membrana específico da próstata (amep) humanizado e fármaco
CN111417655A (zh) 2018-08-28 2020-07-14 润俊(中国)有限公司 抗cd3抗体叶酸生物偶联物及其用途
EP3849614B1 (de) 2018-09-11 2023-12-20 Ambrx, Inc. Interleukin-2-polypeptidkonjugate und deren verwendungen
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
CA3128081A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
IL296099A (en) 2020-03-11 2022-11-01 Ambrx Inc Interleukin-2 polypeptide conjugates and methods of using them
CN116419747B (zh) 2020-08-07 2025-10-17 福蒂斯治疗公司 靶向cd46的免疫偶联物及其使用方法
US20230302150A1 (en) 2020-08-20 2023-09-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
JP2025535713A (ja) 2022-10-07 2025-10-28 アンブレツクス・インコーポレイテツド 薬物リンカー及びその抗体コンジュゲート
KR20250134670A (ko) 2023-01-16 2025-09-11 암브룩스, 인코포레이티드 항-cd70 항체-약물 접합체
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
WO2025041055A1 (en) 2023-08-22 2025-02-27 Ambrx, Inc. Anti-psma adc conjugate compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
FR2466252A2 (fr) * 1979-10-03 1981-04-10 Clin Midy Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine

Also Published As

Publication number Publication date
PL235981A1 (de) 1982-10-25
DE3268752D1 (en) 1986-03-13
AU8251082A (en) 1983-04-21
IE820815L (en) 1982-10-15
US4414148A (en) 1983-11-08
PT74741B (fr) 1983-11-09
EP0063988A1 (de) 1982-11-03
MA19429A1 (fr) 1982-12-31
FR2504010A1 (fr) 1982-10-22
NO154905B (no) 1986-10-06
FI821304L (fi) 1982-10-16
DK167482A (da) 1982-10-16
IE53009B1 (en) 1988-05-11
EP0063988B1 (de) 1986-01-29
KR880001045B1 (ko) 1988-06-18
CA1195248A (en) 1985-10-15
ATE17653T1 (de) 1986-02-15
FI76693C (fi) 1988-12-12
GR69199B (de) 1982-05-06
PT74741A (fr) 1982-05-01
IL65441A0 (en) 1982-07-30
SU1329604A3 (ru) 1987-08-07
FR2504010B1 (fr) 1985-10-25
HU188314B (en) 1986-04-28
DK159277C (da) 1991-02-18
AU556641B2 (en) 1986-11-13
KR830009777A (ko) 1983-12-23
ES8303918A1 (es) 1983-02-16
FI76693B (fi) 1988-08-31
CZ256482A3 (en) 1994-01-19
ES511433A0 (es) 1983-02-16
YU83082A (en) 1985-03-20
NO154905C (no) 1987-01-14
PH20846A (en) 1987-05-08
NO821198L (no) 1982-10-18
FI821304A0 (fi) 1982-04-14
JPS57179124A (en) 1982-11-04
AR228394A1 (es) 1983-02-28
NZ200302A (en) 1985-03-20
DK159277B (da) 1990-09-24
DD204849A5 (de) 1983-12-14
ZA822528B (en) 1983-02-23
PL135800B1 (en) 1985-12-31
EG15718A (en) 1986-09-30

Similar Documents

Publication Publication Date Title
OA07069A (fr) Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation.
OA07103A (fr) Nouvelles 1,2-diaminocyclobutène-3,4-diones, leur procédé de préparation et composition pharmaceutique les contenant.
DZ312A1 (fr) Interferons et procédé pour leur préparation.
IT1150682B (it) Procedimento per la produzione di sostanze prodotte da cellule,particolarmente di anticorpi e simili
FR2516794B1 (fr) Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
FR2552222B1 (fr) Ensemble d'accelerometres pour plate-forme inertielle et plate-forme inertielle le comportant
FI822964A0 (fi) Med laosanordning foersedd icke-metallisk biologiskt anpassbar blodkaerlsklaemma
OA05638A (fr) Nouveaux agents anthelminthiques et procédés pour leur préparation.
FR2434201B1 (fr) Procede et necessaire de determination et de dosage immunologique d'une substance par creation d'un micro-environnement concentre
OA08444A (fr) Nouveaux céphèmes et procédés pour leur préparation.
IT8719086A0 (it) Immunoglobulina iniettabile per via endovenosa con un elevato titolo di anticorpi contro il virussinciziale respiratorio, procedimento per la sua produzione e preparato farmaceutico che lo contiene.
FR2527928B1 (fr) Procede de preparation d'anticorps monoclonaux conjugues avec un chelate metallique et solution les contenant
OA05575A (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation ainsi que les compositions les contenant.
OA09190A (fr) "Procédés de préparation de dérivés d'acides benzocycloalcényl dihydroxy alcanoïques et de médicaments les contenant".
OA04772A (fr) Nouveaux dérivés d'imidazolidine utiles à la lutte contre les parasites et procédé pour leur préparation.
PT73763B (fr) Procede pour la preparation de nouveaux epoxides d'alkaloides benzofenantridiniques et de compositions pharmaceutiques qui les contiennent
OA07341A (fr) Nouveaux oximéthers, procédé pour leur préparation, agents contenant les nouveaux oximéthers et leur application.
FR2511155B1 (fr) Detection d'anticorps auto-bloquant
OA06794A (fr) 2-Nitroimidazoles, et procédés pour leur préparation.
IL77990A (en) Monoclonal anti-alpha-amylase antibody,process for obtaining the same and pharmaceutical compositions containing the same
FR2503713B1 (fr) 2,3-di-substitue-5,6-dihydro-imidazo-(2,1-b) thiazoles, procede pour leur preparation et agents anti-inflammatoires les contenant
OA08494A (fr) Nouveaux polypeptides, leur procédé d'obtention, anticorps monoclonaux spécifiques pour ces polypeptides, et utilisation de ces polypeptides.
BE841741A (fr) Agents d'addition anti-rouille pour lubrifiants et combustibles liquides, procede pour leur preparation, et produits qui en contiennent
NL186860C (nl) N,n'-bis-(3-picolyl)-4-methoxy-isoftalamidemonohydraat, werkwijze voor de bereiding daarvan en farmaceutische preparaten, die dit bevatten.
FR2405731B1 (fr) Colonne de distillation a cloches a bulles d'entretien facile, pour distillation de liquides encrassants et/ou a forts depots